The breakthrough was disclosed by Veronika Skvortsova, director of the Federal Medical-Biological Agency (FMBA).

According to Skvortsova the vaccine is based on mRNA technology, the same platform used in several COVID-19 vaccines. This approach enables the body’s cells to produce proteins resembling those on cancer cells, effectively training the immune system to detect and eliminate malignant cells.

Announcing the breakthrough at the Eastern Economic Forum (EEF), Veronika Skvortsova said the project had been in development for several years, with the past three dedicated to mandatory preclinical studies. “The vaccine is now ready for use; we are awaiting official approval,” she confirmed.

During preclinical trials, researchers observed significant tumor reductions and slowed cancer progression by 60% to 80%, depending on the disease. The vaccine also showed potential to improve survival rates, though experts worldwide continue to call for more detailed clinical data.

Also Read: ‘It saved my life.’ The people turning to AI for therapy

Enteromix is being developed not only for colorectal cancer but also for glioblastoma and several forms of melanoma, including ocular melanoma. These are among the most aggressive and hard-to-treat cancers, with studies now in advanced stages.

Colon Cancer – A Growing Concern

Colon cancer, the initial target of Enteromix, begins in the colon—the first and longest section of the large intestine. Once largely seen in older adults, cases have been rising sharply among younger populations in recent decades. According to the WHO, colon cancer is the third most common cancer worldwide, responsible for about 10% of all cases and the second leading cause of cancer-related deaths.

Lifestyle factors such as high consumption of processed meats, low fruit and vegetable intake, obesity, smoking, alcohol abuse and sedentary habits are among the leading risks.